Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma

Medical Science Monitor

Volumn 8, Issue 4, 2002, Pages

  Ciepłuch, Hanna ^a   Baran, Wojciech ^a   Hellmann, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bisphosphonates; Multiple myeloma; Pamidronate; Resistance to treatment; Thalidomide

Indexed keywords

PAMIDRONIC ACID; THALIDOMIDE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; POLYNEUROPATHY; SOMNOLENCE; T LYMPHOCYTE ACTIVATION; VERTIGO;

EID: 0036236390     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Berenson: Pathogenesis and management of bone lesions in multiple myeloma
2. Bisphosphonates - Preclinical
3. Multiple myeloma: Increasing evidence for a multistep transformation process
4. Growth and induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
5. Multiple myeloma: New insights and therapeutic approaches
6. Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
7. Inhibition of matrix metalloproteinase by bisphosphonates may in part explain their effects in the treatment of multiple myeloma
8. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
9. The role of bisphosphonates in multiple myeloma
10. Thalidomide - New possibilities of treatment of plasmocytic myeloma
11. Thalidomide - A revival story
12. Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma
13. Thalidomide in monoterapy and in combination with dexamethasone in patients with treatment resistant forms of multiple myeloma
14. STEPS: A comprehensive program for controlling and monitoring access to thalidomide
15. Antitumor activity of thalidomide in refractory multiple myeloma
16. Thalidomide treatment of resistant or relapsed multiple myeloma patients
17. Thalidomide in patients with advanced multiple myeloma
18. Swedish experience of thalidomide treatment in myeloma
19. Thalidomide and its analogs overcome drug resistance of human myeloma cells to conventional therapy
20. Bisphosphonates in multiple myeloma
21. Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma